Low Seroprevalence of SARS-CoV-2 Antibodies in Cirrhotic Patients

Patients with underlying liver cirrhosis and coronavirus disease 2019 (COVID-19) seem to be at increased risk of adverse outcomes due to both hepatic decompensation and respiratory failure, as described in recent studies from all over the world [1–3]. Despite the efforts to promote two combined worldwide registries, the reported cumulative number of cirrhotic patients with an outcome in literature is far lower than 1000 individuals out of more than 27 million COVID-19 cases worldwide [4]. Cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with liver cirrhosis mainly come from hospitalized cohorts and suffer from reporting biases, thus cannot be extended to the whole population of cirrhotic patients.